Cancer drug maker gave last-minute discount deal to HSE

The HSE declined to disclose the price reduction secured

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
12th June, 2016
HSE director general Tony OBrien

The HSE secured a discount on the cancer medicine Pembrolizumab, after the manufacturer offered a last-minute price reduction.

In a letter to health minister Simon Harris, HSE director general Tony O’Brien said pharmaceutical company MSD had offered “revised commercial terms” in May.

In his June 2 letter to Harris, O’Brien confirmed that the HSE directorate had approved funding of the medicine, dubbed ‘Pembro’, which is used to treat advanced melanoma –...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Analysis: Daily Covid cases could drop below 50 by March 5 if current rate continues

Health Rachel Lavin 3 hours ago

Dentist to the reality stars sets up Dublin clinic

Health Killian Woods 2 days ago

Tony O’Brien: We need a face and a voice to lead the vaccine rollout

Health Tony O'Brien 3 days ago

Cathal Mac Coille: New Covid strains make credible travel restrictions essential